Liso-Cel Transgene 動態のモデリングによる実証
Bristol Myers Squibb (BMS) sought to develop lisocabtagene maraleucel, a CAR-T cell therapy, to treat patients with relapsed/refractory large B-cell lymphoma. Historically, large between-subject variability has been noted with CAR T-cell therapies. The client needed to understand how patient characteristics might contribute to CAR T-cell expansion variability. Certara developed a population cellular kinetic model to characterize the kinetics of the liso-cel transgene, via quantitative polymerase chain reaction assessment after intravenous infusion of liso-cel, and to understand covariates that might influence liso-cel kinetics in individual patients.